Skip to main content
. 2018 Apr 13;9:742. doi: 10.3389/fimmu.2018.00742

Figure 5.

Figure 5

Evaluating the outcome on efferocytosis after treatment with MER-specific antibodies, Mertk gene ablation or Pros1 overexpression. (A) Immunohistochemical staining for cleaved Caspase-3 in knee joints of collagen-induced arthritis (CIA) mice injected with IgG or anti-MER. Shown are representative pictures of knee joint sections with similar microscopic scores of inflammation, in two different magnifications. (B) Pictures of knee joint sections shown in (A) were quantified and the cleaved Caspase-3 positive area was corrected by the total inflamed area (n = 10–12 knee joints). (C) Quantification of immunohistochemical staining for cleaved Caspase-3 in knee joints of wild-type (WT) or Mertk−/− mice with KRN serum transfer arthritis (STA) mice (n = 10–18 knee joints). (D) Quantification of immunohistochemical staining for cleaved Caspase-3 in knee joints of CIA mice intravenously injected with Ad Luc or Ad Pros1 (n = 18 knee joints). (E) Quantification of immunohistochemical staining for cleaved Caspase-3 in knee joints of KRN STA mice intra-articularly injected with Ad Luc or Ad Pros1 (n = 12 knee joints). P, patella; F, femur; S, synovium. For (B–E), data are presented as mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001 with unpaired t-test. See also Figure S5 in Supplementary Material.